MORRISVILLE – Biopharma firm Liquidia has struck a deal for $100 million in capital that it says “extends [its] cash runway” and provides funds for launch of its lead product that targets  pulmonary arterial hypertension if and when patent litigation over the treatment is resolved with United Therapeutics.

For details, read the full announcement at: